Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic bacterial infection models for BRM screening.

G Dickneite, H U Schorlemmer, H H Sedlacek

    Behring Institute Mitteilungen
    |May 1, 1984
    PubMed
    Summary

    Bestatin, an immunostimulating drug, demonstrated both therapeutic and prophylactic effects against chronic bacterial infections in mice. It reduced bacterial colonization and lesion formation by enhancing macrophage activity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.

    Journal of thrombosis and haemostasis : JTH·2015
    Same author

    Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).

    Journal of thrombosis and haemostasis : JTH·2014
    Same author

    Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.

    Journal of thrombosis and haemostasis : JTH·2012
    Same author

    Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

    Journal of thrombosis and haemostasis : JTH·2012
    Same author

    Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.

    Haemophilia : the official journal of the World Federation of Hemophilia·2011
    Same author

    Reduction of r-hirudin induced bleeding in pigs by the administration of von Willebrand factor.

    Platelets·2010

    Area of Science:

    • Immunology
    • Pharmacology
    • Microbiology

    Background:

    • Chronic infections necessitate effective therapeutic and prophylactic agents.
    • Biological Response Modifiers (BRMs) are investigated for their immunomodulatory potential.
    • Bestatin, a dipeptide derived from Streptomyces olivoreticuli, is an immunostimulating drug.

    Purpose of the Study:

    • To evaluate the therapeutic and prophylactic efficacy of Bestatin in chronic bacterial infection models.
    • To investigate Bestatin's effects on immune responses, specifically macrophage activity and delayed type hypersensitivity.

    Main Methods:

    • Utilized chronic infection models in NRMI mice, induced by Salmonella typhimurium and a nephropathogenic Escherichia coli strain.
    • Assessed Bestatin's prophylactic and therapeutic effects by measuring bacterial organ colonization and lesion formation.
    • Evaluated Bestatin's impact on macrophage activity and delayed type hypersensitivity (DTH).

    Main Results:

    • Bestatin exhibited both prophylactic and therapeutic activity in both infection models.
    • Reduced bacterial organ colonization and inhibited organ lesion formation were observed.
    • Bestatin stimulated macrophage activity and potentiated delayed type hypersensitivity, but did not affect the humoral immune response.

    Conclusions:

    • Bestatin is a potent biological response modifier effective against chronic bacterial infections.
    • Its efficacy is linked to the stimulation of cellular immunity, particularly macrophage activity and DTH.
    • Bestatin holds promise as a therapeutic and prophylactic agent for bacterial infections.

    Related Experiment Videos